The Val30Met familial amyloid polyneuropathy specific Rasch-built overall disability scale (FAP-RODS©)

Journal of the Peripheral Nervous System

Volumn 20, Issue 3, 2015, Pages 319-327

  Pruppers, Mariëlle H J ^a   Merkies, Ingemar S J ^a,b   Faber, Catharina G ^a   Da Silva, Ana M ^c   Costa, Vanessa ^c   Coelho, Teresa ^c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Infection and Immunology   (Netherlands)

^c HOSPITAL DE SANTO ANTÓNIO   (Portugal)

Author keywords

activity and participation; familial amyloid polyneuropathy; outcome research; Rasch built disability scale; validity and reliability

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FAMILIAL AMYLOID POLYNEUROPATHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT HISTORY OF LIVER TRANSPLANTATION; PHYSICAL DISABILITY; PORTUGAL; PRIORITY JOURNAL; RASCH ANALYSIS; SOCIAL PARTICIPATION; SPECIFIC RASCH BUILT OVERALL DISABILITY SCALE; TEST RETEST RELIABILITY; VALIDATION STUDY; VALIDITY; DAILY LIFE ACTIVITY; DISABILITY; GENETICS; MIDDLE AGED; MUTATION; PATHOPHYSIOLOGY; QUESTIONNAIRE; REPRODUCIBILITY; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX;

METHIONINE; PREALBUMIN; VALINE;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AMYLOID NEUROPATHIES, FAMILIAL; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; METHIONINE; MIDDLE AGED; MUTATION; OUTCOME ASSESSMENT (HEALTH CARE); PORTUGAL; PREALBUMIN; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; VALINE;

EID: 84941753188     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/jns.12120     Document Type: Article

References (44)

1. Adams D, Lozeron P, Lacroix C, (2012). Amyloid neuropathies. Curr Opin Neurol 25: 564-572.
2. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Plante-Bordeneuve V, Rapezzi C, Said G, Salvi F, (2013). Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 8: 31.
3. Andrich D, Sheridan B, Luo G, (2010). Rasch Models for Measurement: RUMM2030. RUMM Laboratory, Perth.
4. Berk JL, Dyck PJ, Obici L, Zeldenrust SR, Sekijima Y, Yamashita T, Ando Y, Ikeda SI, Gorevic P, Merlini G, Kelly JW, Skinner M, Bisbee AB, Suhr OB, Familial Amyloidosis Consortium (2011). The diflunisal trial: update on study drug tolerance and disease progression. Amyloid 18 (Suppl. 1): 196-197.
5. Berk JL, Suhr OB, Sekijima Y, Yamashita T, Heneghan M, Zeldenrust SR, Ando Y, Ikeda S, Gorevic P, Merlini G, Kelly JW, Skinner M, Bisbee AB, Dyck PJ, Obici L, Familial Amyloidosis Consortium (2012). The diflunisal trial: study accrual and drug tolerance. Amyloid 19 (Suppl. 1): 37-38.
6. Bland JM, Altman DG, (1995). Multiple significance tests: the Bonferroni method. BMJ 310: 170.
7. Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, Powers ET, Wiseman RL, Foss TR, Wilson IA, Kelly JW, Labaudiniere R, (2012). Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 109: 9629-9634.
8. Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plante-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceicao IM, Schmidt HH, Trigo P, Kelly JW, Labaudiniere R, Chan J, Packman J, Wilson A, Grogan DR, (2012). Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79: 785-792.
9. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, Perez J, Chiesa J, Warrington S, Tranter E, Munisamy M, Falzone R, Harrop J, Cehelsky J, Bettencourt BR, Geissler M, Butler JS, Sehgal A, Meyers RE, Chen Q, Borland T, Hutabarat RM, Clausen VA, Alvarez R, Fitzgerald K, Gamba-Vitalo C, Nochur SV, Vaishnaw AK, Sah DW, Gollob JA, Suhr OB, (2013). Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369: 819-829.
10. Connors LH, Richardson AM, Theberge R, Costello CE, (2000). Tabulation of transthyretin (TTR) variants as of 1/1/2000. Amyloid 7: 54-69.
11. Coutinho P, Martins da Silva A, Lopes Lima J, Resende Barbosa A, (1980). Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: Amyloid and Amyloidosis., Glenner GG, Pinho e Costa P, Falcao de Freitas A, (Eds). Excerpta Medica, Amsterdam, pp 88-98.
12. DeVellis RF, (2006). Classical test theory. Med Care 44: S50-S59.
13. Draak TH, Vanhoutte EK, van Nes SI, Gorson KC, Van der Pol WL, Notermans NC, Nobile-Orazio E, Leger JM, Van den Bergh PY, Lauria G, Bril V, Katzberg H, Lunn MP, Pouget J, van der Kooi AJ, Hahn AF, Doorn PA, Cornblath DR, van den Berg LH, Faber CG, Merkies IS, Group obotPS (2014). Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness. Neurology 83: 2124-2132.
14. Dyck PJ, Davies JL, Litchy WJ, O'Brien PC, (1997). Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 49: 229-239.
15. Fisher WP, (1992). Reliability statistics. Rasch Meas Transact 6: 238.
16. Group C-PS (2009). CI-PERINOMS: chemotherapy-induced peripheral neuropathy outcome measures study. J Peripher Nerv Syst 14: 69-71.
17. Guillemin F, Bombardier C, Beaton D, (1993). Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 46: 1417-1432.
18. Hammarstrom P, Wiseman RL, Powers ET, Kelly JW, (2003). Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 299: 713-716.
19. Hermans MC, Faber CG, De Baets MH, de Die-Smulders CE, Merkies IS, (2010). Rasch-built myotonic dystrophy type 1 activity and participation scale (DM1-Activ). Neuromuscul Disord 20: 310-318.
20. Hobart J, Cano S, (2009). Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods. Health Technol Assess 13 (iii, ix-x): 1-177.
21. Hobart JC, Cano SJ, Zajicek JP, Thompson AJ, (2007). Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol 6: 1094-1105.
22. Holmgren G, Steen L, Ekstedt J, Groth CG, Ericzon BG, Eriksson S, Andersen O, Karlberg I, Nordén G, Nakazato M, Hawkins P, Richardson S, Pepys M, (1991). Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 40: 242-246.
23. Koike H, Misu K, Ikeda S, Ando Y, Nakazato M, Ando E, Yamamoto M, Hattori N, Sobue G, Study Group for Hereditary Neuropathy in Japan (2002). Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol 59: 1771-1776.
24. Merbitz C, Morris J, Grip JC, (1989). Ordinal scales and foundations of misinference. Arch Phys Med Rehabil 70: 308-312.
25. Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA, Cause IN, Treatment Group (2003). Connecting impairment, disability, and handicap in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 74: 99-104.
26. Merkies IS, Hughes RA, Donofrio P, Bril V, Dalakas MC, Hanna K, Hartung HP, Latov N, van Doorn PA, Deng C, (2010). Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study. J Peripher Nerv Syst 15: 208-215.
27. Merkies IS, Lauria G, Faber CG, (2012). Outcome measures in peripheral neuropathies: requirements through statements. Curr Opin Neurol 25: 556-563.
28. van Nes SI, Vanhoutte EK, van Doorn PA, Hermans M, Bakkers M, Kuitwaard K, Faber CG, Merkies IS, (2011). Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology 76: 337-345.
29. Pallant JF, Tennant A, (2007). An introduction to the Rasch measurement model: an example using the Hospital Anxiety and Depression Scale (HADS). Br J Clin Psychol 46: 1-18.
30. Plante-Bordeneuve V, Said G, (2011). Familial amyloid polyneuropathy. Lancet Neurol 10: 1086-1097.
31. Rasch G, (1960). Probabilistic Models for Some Intelligence and Attainment Tests. University of Chicago Press, Chicago.
32. Sousa A, Andersson R, Drugge U, Holmgren G, Sandgren O, (1993). Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence. Hum Hered 43: 288-294.
33. Sousa A, Coelho T, Barros J, Sequeiros J, (1995). Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Povoa do Varzim and Vila do Conde (north of Portugal). Am J Med Genet 60: 512-521.
34. Stevens SS, (1946). On the theory of scales of measurement. Science 103: 677-680.
35. Streiner DL, Norman GR, (1998). Health Measurement Scales. A Practical Guide to their Development and Use. Oxford University Press, New York.
36. Suhr OB, (2003). Impact of liver transplantation on familial amyloidotic polyneuropathy (FAP) patients' symptoms and complications. Amyloid 10 (Suppl 1): 77-83.
37. Tennant A, Conaghan PG, (2007). The Rasch measurement model in rheumatology: what is it and why use it? When should it be applied, and what should one look for in a Rasch paper? Arthritis Rheum 57: 1358-1362.
38. Tomas MT, Santa-Clara H, Bruno PM, Monteiro E, Carrolo M, Barroso E, Sardinha LB, Fernhall B, (2013). The impact of exercise training on liver transplanted familial amyloidotic polyneuropathy (FAP) patients. Transplantation 95: 372-377.
39. Vanhoutte EK, Faber CG, Merkies IS, on behalf of the PeriNomS Study group (2013). 196th ENMC international workshop: Outcome measures in inflammatory peripheral neuropathies 8-10 February 2013, Naarden, The Netherlands. Neuromuscul Disord 23: 924-933.
40. Vinik EJ, Hayes RP, Oglesby A, Bastyr E, Barlow P, Ford-Molvik SL, Vinik AI, (2005). The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther 7: 497-508.
41. Vinik EJ, Vinik AI, Paulson JF, Merkies IS, Packman J, Grogan DR, Coelho T, (2014). Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 19: 104-114.
42. World Health Organization (2001). ICF: International Classification of Functioning, Disability and Health. World Health Organization pp III, Geneva, p 299.
43. Wright BD, Linacre JM, (1989). Observations are always ordinal; measurements, however, must be interval. Arch Phys Med Rehabil 70: 857-860.
44. Wright BD, Stone MH, (1979). Best Test Design. Media Press, Chicago.